Knight Therapeutics Inc. (GUD.TO) is on the rise, with shares climbing 1.30% in the latest trading session.
Knight Therapeutics Inc., a Montreal-based pharmaceutical company, has seen its stock price increase by 1.30% recently, closing at CA$9.35. This positive movement comes after a significant announcement about repaying its revolving credit facility, which has boosted investor confidence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$962.16M
P/E
163.3x
52W high
$10.17
52W low
$5.66
1W change
-1.61%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 0.3% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$9.83
+0.3% Upside
Current Price
C$9.80
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
23.6%
Annualized
90-Day Vol
30.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.72
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$10.40 | C$9.59 โ C$11.28 |
| 60 trading days | C$11.04 | C$9.84 โ C$12.39 |
| 90 trading days | C$11.72 | C$10.18 โ C$13.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The repayment of the credit facility shows Knight's strong cash flow and positions the company for future growth, making it an attractive option for investors interested in the pharmaceutical sector.
Knight Therapeutics Inc. Gains 1.30% in One Day
The company's market cap now stands at CA$914 million, reflecting its solid recovery and growth potential in the pharmaceutical market.
Bull case
The successful repayment of the revolving credit facility highlights Knight's strong financial health and operational efficiency. This could lead to increased investor confidence and further appreciation in stock price.
Bear case
Despite the positive news, Knight's high P/E ratio of 153.83 raises concerns about overvaluation. This suggests that any missteps in future performance could result in significant corrections in stock price.
Strong Financial Management
Knight Therapeutics' recent announcement about repaying its revolving credit facility showcases its commitment to financial prudence. This repayment, funded by strong cash flows, not only reduces debt but also enhances the company's ability to invest and acquire in the pharmaceutical sector.
Market Response and Future Outlook
The market has responded positively to Knight's announcement, reflecting investor confidence in the company's strategic direction. With a market cap of CA$914 million and a solid operational framework, Knight is well-positioned to take advantage of growth opportunities in Canada and Latin America, making it a compelling option for investors.
Advertisement
